IDKmonitor Infliximab TOTAL Anti-drug Antibody ELISA 96 Wells


Infliximab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.

These Anti-drug antibodies bind and neutralise the TNFα inhibitors accelerating their clearance and reduces the efficacy of the drugs.  Monitoring the efficacy of TNFα inhibitors may help clinicians schedule a successful individualised treatment strategy for their patients.

Total Anti-Infliximab Antibody ELISA

TOTAL anti-drug antibody ELISAs enable the detection of anti-drug antibodies in the presence of circulating drug, and so are often called “Drug Tolerant” assays. The benefit of drug-tolerant assays is being able to detect lower titres of Anti-drug antibodies which could become clinically significant in certain circumstances.

Total anti-drug Antibody assays offer a greater sensitivity, unmasking the drug-bound portion of anti-drug antibodies in circulation. TOTAL anti-drug antibody analysis may be advantageous when using combination therapy such as immunosuppressants due to this increased sensitivity.

IDKmonitor® Infliximab total-Anti-drug Antibody ELISA is a quantitative assay that involves a pre-analytical step to dissociate the anti-drug antibodies of interest from the therapeutic Infliximab. The separated therapeutic Infliximab is replaced by a biotinylated version of the drug, forming a the new complex which can be captured and quantified on the streptavidin coated microplate.


  • Drug tolerant assay for Infliximab anti-drug antibodies

  • Detects Total anti-infliximab antibodies in Serum and Plasma

  • Preanalytical step to dissociate therapeutic drug from target anti-drug antibody

  • 1 calibrator, 2 controls

  • Capacity for 45 samples in duplicate

  • Automatable on ELISA automates (e.g. Dynex D2)


  • Supports the investigation of primary non response and loss of response to Infliximab

  • Drug tolerant assay detects total anti-infliximab antibodies (those free- and bound to- infliximab)

  • Helps predict long term outcome of disease in patients with sub-therapeutic infliximab levels

  • Identifies patients with low-titre anti-infliximab antibodies (e.g. in the case of concomitant immunosuppressant)

  • UK publications and evidence base

  • Widely available via reference laboratories in UK and Ireland

  • Applicable to Gastroenterology, Rheumatology